<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2016-2-70-77</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-687</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Напроксен: универсальный анальгет и к с минимальным риском кардиоваскулярных осложнений</article-title><trans-title-group xml:lang="en"><trans-title>Naproxen: A universal analgesic with a minimal risk of cardiovascular events</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. E.</given-names></name></name-alternatives><email xlink:type="simple">aekarateev@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва, Россия 115522, Москва, Каширское шоссе, 34А</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115552</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>05</day><month>06</month><year>2016</year></pub-date><volume>10</volume><issue>2</issue><fpage>70</fpage><lpage>77</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каратеев А.Е., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Каратеев А.Е.</copyright-holder><copyright-holder xml:lang="en">Karateev A.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/687">https://mrj.ima-press.net/mrj/article/view/687</self-uri><abstract><p>Нестероидные противовоспалительные препараты (НПВП) – основной инструмент, используемый в реальной клинической практике для купирования острой боли и контроля основных симптомов при хронических заболеваниях суставов и позвоночника. Они действенны, доступны и удобны в применении, однако могут вызывать нежелательные реакции (НР), которые требуют тщательного контроля и эффективной профилактики. Современная концепция безопасного использования НПВП направлена на максимальное снижение риска осложнений со стороны как желудочно-кишечного тракта (ЖКТ), так и сердечно-сосудистой системы. По данным клинических испытаний и популяционных исследований, среди всех НПВП (кроме аспирина) наименьший риск кардиоваскулярных катастроф отмечен для напроксена. Этот препарат, относящийся к «традиционным» (неселективным) НПВП (н-НПВП), широко используется в клинической практике более 40 лет и завоевал доверие врачей всего мира в качестве надежного анальгетика и противовоспалительного средства. Терапевтический потенциал напроксена доказан при самых разных заболеваниях и патологических состояниях – от острых травм до болезни Бехтерева. При использовании напроксена, как и других н-НПВП, нужно учитывать возможность развития НР со стороны ЖКТ. Однако этот риск может быть существенно снижен при назначении ингибиторов протонной помпы, таких как эзомепразол. В настоящем обзоре приведены основные исследования, в которых изучались эффективность и безопасность напроксена.</p></abstract><trans-abstract xml:lang="en"><p>Nonsteroidal anti-inflammatory drugs (NSAIDs) are a main tool used in real clinical practice to relieve acute pain and to control major symptoms in chronic diseases of the joint and spinal column. They are effective and easy-to-use; however, they may cause adverse reactions (ARs) that require careful monitoring and effective prevention. The current concept of the safe use of NSAIDs is aimed at maximally reducing both gastrointestinal and cardiovascular events. Clinical trials and population-based studies have revealed that among all NSAIDs (other than aspirin), naproxen is associated with the least cardiovascular risk. This drug that belongs to traditional (nonselective) NSAIDs (n-NSAIDs) has been commonly used in clinical practice for more than 40 years and gained physicians’ confidence worldwide as a reliable analgesic and anti-inflammatory agent. The therapeutic potential of naproxen has been proven in a great variety of diseases and abnormalities: from acute injuries to Bechterew’s disease. When using naproxen, like other n-NSAIDs, it should be borne in mind that gastrointestinal ARs may develop. However, this risk may be substantially decreased by the administration of proton pump inhibitors, such as pantoprazole. This review presents basic investigations that have studied the efficacy and safety of naproxen.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>нестероидные противовоспалительные препараты</kwd><kwd>НПВП-гастропатия</kwd><kwd>кардиоваскулярные осложнения</kwd><kwd>профилактика</kwd><kwd>напроксен</kwd><kwd>ингибиторы протонной помпы</kwd></kwd-group><kwd-group xml:lang="en"><kwd>nonsteroidal anti-inflammatory drugs</kwd><kwd>NSAID gastropathy</kwd><kwd>cardiovascular events</kwd><kwd>prevention</kwd><kwd>naproxen</kwd><kwd>proton pump inhibitors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Яхно НН, Кукушкин МЛ, редакторы. Боль: практическое руководство для врачей. Москва: Издательство РАМН; 2012. 512 c. [Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (practical guide for physicians)]. Moscow: Izdatel'stvo RAMN; 2012. 512 p.]</mixed-citation><mixed-citation xml:lang="en">Яхно НН, Кукушкин МЛ, редакторы. Боль: практическое руководство для врачей. Москва: Издательство РАМН; 2012. 512 c. [Yakhno NN, Kukushkin ML, editors. Bol' (prakticheskoe rukovodstvo dlya vrachei) [Pain (practical guide for physicians)]. Moscow: Izdatel'stvo RAMN; 2012. 512 p.]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клиническая фармакология и терапия. 2003;12(1):64-9. [Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya Farmakologiya i Terapiya. 2003;12(1):64-9. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой. Клиническая фармакология и терапия. 2003;12(1):64-9. [Nasonov EL. Analgesic therapy in rheumatology: a journey between Scylla and Charybdis. Klinicheskaya Farmakologiya i Terapiya. 2003;12(1):64-9. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep. 2013 Jan;15(1):300. doi: 10.1007/s11926-012-0300-4.</mixed-citation><mixed-citation xml:lang="en">Lee YC. Effect and treatment of chronic pain in inflammatory arthritis. Curr Rheumatol Rep. 2013 Jan;15(1):300. doi: 10.1007/s11926-012-0300-4.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">van de Laar M, Pergolizzi J, Mellinghoff H, et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs. Open Rheumatol J. 2012;6:320-30. doi: 10.2174/1874312901206010320. Epub 2012 Dec 13.</mixed-citation><mixed-citation xml:lang="en">van de Laar M, Pergolizzi J, Mellinghoff H, et al. Pain Treatment in Arthritis-Related Pain: Beyond NSAIDs. Open Rheumatol J. 2012;6:320-30. doi: 10.2174/1874312901206010320. Epub 2012 Dec 13.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-24. [Karateev AE, Nasonov EL, Yakhno NN et al. Clinical guidelines «Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(1):4- 24. (In Russ.)]. DOI: http://dx.doi.org/10. 14412/1996-7012-2015-1-4-23</mixed-citation><mixed-citation xml:lang="en">Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-24. [Karateev AE, Nasonov EL, Yakhno NN et al. Clinical guidelines «Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(1):4- 24. (In Russ.)]. DOI: http://dx.doi.org/10. 14412/1996-7012-2015-1-4-23</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi: 10.1186/s12916-015-0285-8.</mixed-citation><mixed-citation xml:lang="en">Scarpignato C, Lanas A, Blandizzi C, et al. Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis – an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Med. 2015 Mar 19;13:55. doi: 10.1186/s12916-015-0285-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47.</mixed-citation><mixed-citation xml:lang="en">Harirforoosh S, Asghar W, Jamali F. Adverse Effects of Nonsteroidal Antiinflammatory Drugs: An Update of Gastrointestinal, Cardiovascular and Renal Complications. J Pharm Pharm Sci. 2013;16(5):821-47.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Попкова ТВ, Новикова ДС и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2. Научно-практическая ревматология. 2014;52(6):600–6. [Karateev AE, Popkova TV, Novikova DS, et al. Assessment of risk for gastrointestinal and cardiovascular complications associated with the use of nonsteroidal anti-inflammatory drugs in the CIS population: preliminary data of the CORONA-2 epidemiological survey. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):600–6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-600-606</mixed-citation><mixed-citation xml:lang="en">Каратеев АЕ, Попкова ТВ, Новикова ДС и др. Оценка риска желудочно-кишечных и сердечно-сосудистых осложнений, ассоциированных с приемом нестероидных противовоспалительных препаратов в популяции СНГ: предварительные данные эпидемиологического исследования КОРОНА-2. Научно-практическая ревматология. 2014;52(6):600–6. [Karateev AE, Popkova TV, Novikova DS, et al. Assessment of risk for gastrointestinal and cardiovascular complications associated with the use of nonsteroidal anti-inflammatory drugs in the CIS population: preliminary data of the CORONA-2 epidemiological survey. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):600–6. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1995-4484-2014-600-606</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Capone M, Tacconelli S, Sciulli M, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther. 2007 Aug;322(2): 453-60. Epub 2007 May 1.</mixed-citation><mixed-citation xml:lang="en">Capone M, Tacconelli S, Sciulli M, et al. Human pharmacology of naproxen sodium. J Pharmacol Exp Ther. 2007 Aug;322(2): 453-60. Epub 2007 May 1.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">McGettigan P, Henry D. Use of Non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle- and high- income countries. PLoS Med. 2013;10(2):e1001388. doi: 10.1371/journal.pmed.1001388. Epub 2013 Feb 12.</mixed-citation><mixed-citation xml:lang="en">McGettigan P, Henry D. Use of Non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle- and high- income countries. PLoS Med. 2013;10(2):e1001388. doi: 10.1371/journal.pmed.1001388. Epub 2013 Feb 12.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Runkel R, Chaplin M, Boost G, et al. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci. 1972 May;61(5):703-8.</mixed-citation><mixed-citation xml:lang="en">Runkel R, Chaplin M, Boost G, et al. Absorption, distribution, metabolism, and excretion of naproxen in various laboratory animals and human subjects. J Pharm Sci. 1972 May;61(5):703-8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Aeidler H. Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis. Arzneimittelforschung. 1975 Feb;25(2A):315-8.</mixed-citation><mixed-citation xml:lang="en">Aeidler H. Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis. Arzneimittelforschung. 1975 Feb;25(2A):315-8.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bowers D, Dyer H, Fosdick W, et al. Naproxen in rheumatoid arthritis. A controlled trial. Ann Intern Med. 1975 Oct;83(4):470-5.</mixed-citation><mixed-citation xml:lang="en">Bowers D, Dyer H, Fosdick W, et al. Naproxen in rheumatoid arthritis. A controlled trial. Ann Intern Med. 1975 Oct;83(4):470-5.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Clarke A. A Double-blind comparison of naproxen against indometacin in osteoarthrosis. Arzneimittelforschung. 1975 Feb;25(2A):302-4.</mixed-citation><mixed-citation xml:lang="en">Clarke A. A Double-blind comparison of naproxen against indometacin in osteoarthrosis. Arzneimittelforschung. 1975 Feb;25(2A):302-4.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Castles J, Moore T, Vaughan J, et al. Multicenter comparison of naproxen and indomethacin in rheumatoid arthritis. Arch Intern Med. 1978 Mar;138(3):362-6.</mixed-citation><mixed-citation xml:lang="en">Castles J, Moore T, Vaughan J, et al. Multicenter comparison of naproxen and indomethacin in rheumatoid arthritis. Arch Intern Med. 1978 Mar;138(3):362-6.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Blechman W, Willkens R, Boncaldo G, et al. Naproxen in osteoarthrosis. Doubleblind crossover trial. Ann Rheum Dis. 1978 Feb;37(1):80-4.</mixed-citation><mixed-citation xml:lang="en">Blechman W, Willkens R, Boncaldo G, et al. Naproxen in osteoarthrosis. Doubleblind crossover trial. Ann Rheum Dis. 1978 Feb;37(1):80-4.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Melton JW 3rd, Lussier A, Ward JR, et al. Naproxen vs. aspirin in osteoarthritis of the hip and knee. J Rheumatol. 1978 Fall;5(3):338-46.</mixed-citation><mixed-citation xml:lang="en">Melton JW 3rd, Lussier A, Ward JR, et al. Naproxen vs. aspirin in osteoarthritis of the hip and knee. J Rheumatol. 1978 Fall;5(3):338-46.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Lavin M, Holman K, Smyth C, Vaughan J. A comparison of naproxen, indomethacin and aspirin in osteoarthritis. J Rheumatol. 1980 Sep-Oct;7(5):711-6.</mixed-citation><mixed-citation xml:lang="en">Martinez-Lavin M, Holman K, Smyth C, Vaughan J. A comparison of naproxen, indomethacin and aspirin in osteoarthritis. J Rheumatol. 1980 Sep-Oct;7(5):711-6.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Bjö rkenheim J, Helland J, Peltonen J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. J Int Med Res. 1985;13(5):263-9.</mixed-citation><mixed-citation xml:lang="en">Bjö rkenheim J, Helland J, Peltonen J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. J Int Med Res. 1985;13(5):263-9.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dunn T, Clark V, Jones G. Preoperative oral naproxen for pain relief after day-case laparoscopic sterilization. Br J Anaesth. 1995 Jul;75(1):12-4.</mixed-citation><mixed-citation xml:lang="en">Dunn T, Clark V, Jones G. Preoperative oral naproxen for pain relief after day-case laparoscopic sterilization. Br J Anaesth. 1995 Jul;75(1):12-4.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Comfort V, Code W, Rooney M, Yip R. Naproxen premedication reduces postoperative tubal ligation pain. Can J Anaesth. 1992 Apr;39(4):349-52.</mixed-citation><mixed-citation xml:lang="en">Comfort V, Code W, Rooney M, Yip R. Naproxen premedication reduces postoperative tubal ligation pain. Can J Anaesth. 1992 Apr;39(4):349-52.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Code W, Yip R, Rooney M, et al. Preoperative naproxen sodium reduces postoperative pain following arthroscopic knee surgery. Can J Anaesth. 1994 Feb;41(2):98-101.</mixed-citation><mixed-citation xml:lang="en">Code W, Yip R, Rooney M, et al. Preoperative naproxen sodium reduces postoperative pain following arthroscopic knee surgery. Can J Anaesth. 1994 Feb;41(2):98-101.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Malmstrom K, Kotey P, Coughlin H, Desjardins P. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain. 2004 May-Jun;20(3):147-55.</mixed-citation><mixed-citation xml:lang="en">Malmstrom K, Kotey P, Coughlin H, Desjardins P. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain. 2004 May-Jun;20(3):147-55.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004234. doi: 10.1002/14651858.CD004234.pub3.</mixed-citation><mixed-citation xml:lang="en">Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004234. doi: 10.1002/14651858.CD004234.pub3.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Simmons R, Owen S, Abbott C, et al. Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries – a multicentre comparative study. Br J Sports Med. 1982 Jun;16(2):91-5.</mixed-citation><mixed-citation xml:lang="en">Simmons R, Owen S, Abbott C, et al. Naproxen sodium and paracetamol/dextropropoxyphene in sports injuries – a multicentre comparative study. Br J Sports Med. 1982 Jun;16(2):91-5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Fathi M, Zare MA, Bahmani HR, Zehtabchi S. Comparison of oral oxycodone and naproxen in soft tissue injury pain control: a double-blind randomized clinical trial. Am J Emerg Med. 2015 Sep;33(9):1205-8. doi: 10.1016/j.ajem.2015.05.021. Epub 2015 May 29.</mixed-citation><mixed-citation xml:lang="en">Fathi M, Zare MA, Bahmani HR, Zehtabchi S. Comparison of oral oxycodone and naproxen in soft tissue injury pain control: a double-blind randomized clinical trial. Am J Emerg Med. 2015 Sep;33(9):1205-8. doi: 10.1016/j.ajem.2015.05.021. Epub 2015 May 29.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman BW, Dym AA, Davitt M, et al. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. JAMA. 2015 Oct 20;314(15):1572-80. doi: 10.1001/jama.2015.13043.</mixed-citation><mixed-citation xml:lang="en">Friedman BW, Dym AA, Davitt M, et al. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. JAMA. 2015 Oct 20;314(15):1572-80. doi: 10.1001/jama.2015.13043.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Sturge RA, Scott JT, Hamilton EB, et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis. 1977 Feb;36(1):80-2.</mixed-citation><mixed-citation xml:lang="en">Sturge RA, Scott JT, Hamilton EB, et al. Multicentre trial of naproxen and phenylbutazone in acute gout. Ann Rheum Dis. 1977 Feb;36(1):80-2.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991;12(7):423-9.</mixed-citation><mixed-citation xml:lang="en">Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac ('Lodine') compared with naproxen in patients with acute gout. Curr Med Res Opin. 1991;12(7):423-9.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140</mixed-citation><mixed-citation xml:lang="en">Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014 Nov;53(11):1920-6. doi: 10.1093/rheumatology/keu157. Epub 2014 Apr 23.</mixed-citation><mixed-citation xml:lang="en">Latourte A, Bardin T, Richette P. Prophylaxis for acute gout flares after initiation of urate-lowering therapy. Rheumatology (Oxford). 2014 Nov;53(11):1920-6. doi: 10.1093/rheumatology/keu157. Epub 2014 Apr 23.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.</mixed-citation><mixed-citation xml:lang="en">Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006 Mar;119(3):255-66.</mixed-citation><mixed-citation xml:lang="en">Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006 Mar;119(3):255-66.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Bombardier C, Laine L, Reicin A, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528</mixed-citation><mixed-citation xml:lang="en">Bombardier C, Laine L, Reicin A, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Farkouh M, Kirshner H, Harrington R, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004 Aug 21-27;364(9435):675-84.</mixed-citation><mixed-citation xml:lang="en">Farkouh M, Kirshner H, Harrington R, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004 Aug 21-27;364(9435):675-84.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010 Feb;69(2):374-9. doi: 10.1136/ard.2009.107805. Epub 2009 Apr 12.</mixed-citation><mixed-citation xml:lang="en">Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010 Feb;69(2):374-9. doi: 10.1136/ard.2009.107805. Epub 2009 Apr 12.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Song G, Seo Y, Kim J, et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. J Rheumatol. 2016 Jan 14. [Epub ahead of print]</mixed-citation><mixed-citation xml:lang="en">Song G, Seo Y, Kim J, et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis : A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. J Rheumatol. 2016 Jan 14. [Epub ahead of print]</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Kroon FP, van der Burg LR, Ramiro S, et al. Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. J Rheumatol. 2016 Feb 1. pii: jrheum.150721. [Epub ahead of print]</mixed-citation><mixed-citation xml:lang="en">Kroon FP, van der Burg LR, Ramiro S, et al. Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review. J Rheumatol. 2016 Feb 1. pii: jrheum.150721. [Epub ahead of print]</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014 Jan;73(1):101-7. doi: 10.1136/annrheumdis-2012-203201. Epub 2013 May 21.</mixed-citation><mixed-citation xml:lang="en">Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014 Jan;73(1):101-7. doi: 10.1136/annrheumdis-2012-203201. Epub 2013 May 21.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002 May 22;3:10.</mixed-citation><mixed-citation xml:lang="en">Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. BMC Fam Pract. 2002 May 22;3:10.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Van Hecken A, Schwartz J, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.</mixed-citation><mixed-citation xml:lang="en">Van Hecken A, Schwartz J, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Hinz B, Cheremina O, Besz D, et al. Impact of naproxen sodium at over-thecounter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther. 2008 Apr;46(4):180-6.</mixed-citation><mixed-citation xml:lang="en">Hinz B, Cheremina O, Besz D, et al. Impact of naproxen sodium at over-thecounter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther. 2008 Apr;46(4):180-6.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Schiff M, Hochberg M, Oldenhof J, Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin. 2009 Oct;25(10):2471-7. doi: 10.1185/030079 90903185706.</mixed-citation><mixed-citation xml:lang="en">Schiff M, Hochberg M, Oldenhof J, Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin. 2009 Oct;25(10):2471-7. doi: 10.1185/030079 90903185706.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086.</mixed-citation><mixed-citation xml:lang="en">Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Varas-Lorenzo С, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):559-70.</mixed-citation><mixed-citation xml:lang="en">Varas-Lorenzo С, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):559-70.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Ray W, Varas-Lorenzo C, Chung C, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES. 108.805689. Epub 2009 May 5.</mixed-citation><mixed-citation xml:lang="en">Ray W, Varas-Lorenzo C, Chung C, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES. 108.805689. Epub 2009 May 5.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Gislason G, Rasmussen J, Abildstrom S, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009 Jan 26;169(2): 141-9. doi: 10.1001/archinternmed.2008.525.</mixed-citation><mixed-citation xml:lang="en">Gislason G, Rasmussen J, Abildstrom S, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009 Jan 26;169(2): 141-9. doi: 10.1001/archinternmed.2008.525.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Roumie C, Choma N, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular eventsstroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820.</mixed-citation><mixed-citation xml:lang="en">Roumie C, Choma N, Kaltenbach L, et al. Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular eventsstroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.</mixed-citation><mixed-citation xml:lang="en">Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Antman E, Bennett J, Daugherty A, et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007 Mar 27; 115(12):1634-42. Epub 2007 Feb 26.</mixed-citation><mixed-citation xml:lang="en">Antman E, Bennett J, Daugherty A, et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007 Mar 27; 115(12):1634-42. Epub 2007 Feb 26.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi: 10.1136/ard.2010. 128660. Epub 2010 Sep 10.</mixed-citation><mixed-citation xml:lang="en">Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May;70(5):818-22. doi: 10.1136/ard.2010. 128660. Epub 2010 Sep 10.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Henry D, Lim L, Garcia Rodriguez L, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun 22; 312(7046):1563-6.</mixed-citation><mixed-citation xml:lang="en">Henry D, Lim L, Garcia Rodriguez L, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ. 1996 Jun 22; 312(7046):1563-6.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAIDinduced mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S5. doi: 10.1186/ar4177. Epub 2013 Jul 24.</mixed-citation><mixed-citation xml:lang="en">Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAIDinduced mucosal damage. Arthritis Res Ther. 2013;15 Suppl 3:S5. doi: 10.1186/ar4177. Epub 2013 Jul 24.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. doi: 10.2147/DHPS.S71976.eCollection 2015.</mixed-citation><mixed-citation xml:lang="en">Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. doi: 10.2147/DHPS.S71976.eCollection 2015.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein J, Hochberg M, Fort J, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010 Aug;32(3):401-13. doi: 10.1111/j.1365-2036.2010.04378.x. Epub 2010 May 22.</mixed-citation><mixed-citation xml:lang="en">Goldstein J, Hochberg M, Fort J, et al. Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmacol Ther. 2010 Aug;32(3):401-13. doi: 10.1111/j.1365-2036.2010.04378.x. Epub 2010 May 22.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Sostek M, Fort J, Estborn L, et al. Longterm safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin. 2011 Apr;27(4):847-54. doi: 10.1185/03007995.2011. 555756. Epub 2011 Feb 14.</mixed-citation><mixed-citation xml:lang="en">Sostek M, Fort J, Estborn L, et al. Longterm safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers. Curr Med Res Opin. 2011 Apr;27(4):847-54. doi: 10.1185/03007995.2011. 555756. Epub 2011 Feb 14.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Chang CC, Chiou CS, Lin HL, et al. Increased Risk of Acute Pancreatitis in Patients with Rheumatoid Arthritis: A Population-Based Cohort Study. PLoS One. 2015 Aug 11;10(8):e0135187. doi: 10.1371/journal.pone.0135187. eCollection 2015.</mixed-citation><mixed-citation xml:lang="en">Chang CC, Chiou CS, Lin HL, et al. Increased Risk of Acute Pancreatitis in Patients with Rheumatoid Arthritis: A Population-Based Cohort Study. PLoS One. 2015 Aug 11;10(8):e0135187. doi: 10.1371/journal.pone.0135187. eCollection 2015.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Sorensen HT, Jacobsen J, Norgaard M, et al. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther. 2006 Jul 1;24(1):111-6.</mixed-citation><mixed-citation xml:lang="en">Sorensen HT, Jacobsen J, Norgaard M, et al. Newer cyclo-oxygenase-2 selective inhibitors, other non-steroidal anti-inflammatory drugs and the risk of acute pancreatitis. Aliment Pharmacol Ther. 2006 Jul 1;24(1):111-6.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Камчатнов ПР, Умарова ХЯ, Чугунов АВ. Боль в спине: проблемы выбора адекватной терапии. Consilium medicum. Неврология и ревматология (Прил). 2015;(2):22-6. [Kamchatnov PR, Umarova KhYa, Chugunov AV. Back pain: the problem of choice of adequate therapy. Consilium medicum. Neurology and rheumatology (Suppl). 2015;(2):22-6. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Камчатнов ПР, Умарова ХЯ, Чугунов АВ. Боль в спине: проблемы выбора адекватной терапии. Consilium medicum. Неврология и ревматология (Прил). 2015;(2):22-6. [Kamchatnov PR, Umarova KhYa, Chugunov AV. Back pain: the problem of choice of adequate therapy. Consilium medicum. Neurology and rheumatology (Suppl). 2015;(2):22-6. (In Russ.)].</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
